Independent Advisor Alliance Invests $1.78 Million in ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Independent Advisor Alliance acquired a new stake in ADMA Biologics, purchasing 89,475 shares valued at approximately $1.775 million during the first quarter.
• ADMA Biologics reported earnings of $0.15 per share, exceeding expectations, with quarterly revenue of $121.98 million, representing a 13.8% year-over-year increase.
• Several institutional investors increased their positions in ADMA, with hedge funds collectively owning 75.68% of the company's stock, reflecting strong investor interest.

Independent Advisor Alliance bought a new position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 89,475 shares of the biotechnology company's stock, valued at approximately $1,775,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Cetera Investment Advisers lifted its position in shares of ADMA Biologics by 1.3% during the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company's stock valued at $1,002,000 after buying an additional 670 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of ADMA Biologics by 1.1% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company's stock valued at $1,323,000 after purchasing an additional 711 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in ADMA Biologics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock valued at $404,000 after acquiring an additional 746 shares during the period. GF Fund Management CO. LTD. lifted its holdings in ADMA Biologics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company's stock worth $120,000 after buying an additional 1,089 shares during the period. Finally, Journey Strategic Wealth LLC lifted its holdings in ADMA Biologics by 6.6% in the 1st quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company's stock worth $354,000 after buying an additional 1,102 shares during the period. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Stock Up 0.1%

Shares of ADMA traded up $0.02 during midday trading on Friday, hitting $16.99. 3,108,545 shares of the company's stock traded hands, compared to its average volume of 3,154,640. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of 19.76 and a beta of 0.38. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm's fifty day moving average is $18.36 and its 200-day moving average is $18.83. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. The company had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%. The firm's quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter last year, the business posted $0.13 EPS. As a group, sell-side analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. This trade represents a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the transaction, the director directly owned 87,330 shares of the company's stock, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 464,621 shares of company stock worth $9,644,269. Insiders own 3.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial upped their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a research note on Thursday, May 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.